![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Subjects:
96-Week Efficacy and Safety Results of the PROGRESS Study
|
|
|
Reported by Jules Levin
Forty Ninth Infectious Disease Society of America Annual Meeting ·
Boston, Massachusetts ·
20-23 October
Roger Trinh1, Joseph Gathe2, Jacques Reynes3, Federico Pulido4, Ruth Soto-Malave5, Min Tian1, Linda Fredrick1, Thomas Podsadecki1, Michael Norton1, Angela Nilius1
1Abbott, Abbott Park, Illinois; 2Therapeutic Concepts, Houston, Texas; 3Department of Infectious and Tropical Diseases, Montpellier University Hospital, Montpellier, France; 4Unidad VIH. Hospital Universitario 12 de Octubre,
Universidad Complutense de Madrid, Madrid, Spain; 5University of Puerto Rico, School of Medicine, Infectious Diseases Section, San Juan, Puerto Rico and Innovative Care PSC, Bayamon, Puerto Rico
First-Line Darunavir/Raltegravir Riskier With Viral Load Above 100000
www.natap.org/2011/CROI/croi_107.htm
Mar 2, 2011 - People who began a first-line nucleoside-free regimen of darunavir/ritonavir plus raltegravir with a viral load above 100000 copies ran a higher ...
Results from a Single Arm Study of Darunavir/RitonavirPlus ...
www.natap.org/2011/CROI/croi_108.htm
Mar 2, 2011 - Results from a Single Arm Study of Darunavir/RitonavirPlus Raltegravir in Treatment-Naïve HIV-1-Infected Patients (ACTG A5262). Reported by ...
Efficacy of a Nucleoside-sparing Regimen of Darunavir/Ritonavir Plus
www.natap.org/2011/HIV/090611_01.htm -
Efficacy of a Nucleoside-sparing Regimen of Darunavir/Ritonavir Plus Raltegravir in Treatment-Naive HIV-1-infected Patients (ACTG A5262). Download the PDF ...
[PDF]
Efficacy of a Nucleoside-sparing Regimen of Darunavir/Ritonavir Plus
www.natap.org/.../Efficacy_of_a_Nucleoside_sparing_Regimen_of.9...
File Format: PDF/Adobe Acrobat
by B Taiwo - 2011 -
Objective: To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination ... Keywords: antiretroviral therapy, darunavir, nucleoside-sparing, raltegravir ...
![HCV1.gif](../images/110211/110211-6/HCV1.gif)
![HCV2.gif](../images/110211/110211-6/HCV2.gif)
![HCV3.gif](../images/110211/110211-6/HCV3.gif)
![HCV4.gif](../images/110211/110211-6/HCV4.gif)
![HCV5.gif](../images/110211/110211-6/HCV5.gif)
![HCV6.gif](../images/110211/110211-6/HCV6.gif)
![HCV7.gif](../images/110211/110211-6/HCV7.gif)
![HCV8.gif](../images/110211/110211-6/HCV8.gif)
![HCV9.gif](../images/110211/110211-6/HCV9.gif)
![HCV10.gif](../images/110211/110211-6/HCV10.gif)
![HCV11.gif](../images/110211/110211-6/HCV11.gif)
![HCV12.gif](../images/110211/110211-6/HCV12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|